NutriBand (NTRB) Cash from Investing Activities (2018 - 2025)
NutriBand's (NTRB) quarterly Cash from Investing Activities came in at -$5324.0 in Q2 2025, up 14.06% year-on-year from -$4667.7 in Q2 2024, and up 88.66% quarter-over-quarter from -$46958.0 in Q4 2024.
NutriBand (NTRB) Cash from Investing Activities (2018 - 2025) Analysis & Trends
NutriBand has disclosed Cash from Investing Activities across 6 years of filings, most recently posting -$5324.0 for Q2 2025.
- Cash from Investing Activities for Q2 2025 came in at -$5324.0, up 14.06% year-over-year; the trailing twelve-month figure through Jan 2026 was -$5324.0 (up 94.22% YoY), and the FY2026 annual result was -$5324.0, up 94.22% from the prior year.
- Cash from Investing Activities came in at -$5324.0 for Q2 2025 at NutriBand, up from -$46958.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$1272.0 in Q4 2022 to a low of -$49137.0 in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$17411.5 (2021), against an average of -$22144.8.
- Across the five-year window, Cash from Investing Activities soared 94.01% in 2023 and tumbled 390.24% in 2024, its largest moves.
- NutriBand's Cash from Investing Activities stood at -$1992.0 in 2021, then soared by 36.14% to -$1272.0 in 2022, then tumbled by 106.29% to -$2624.0 in 2023, then slumped by 1689.56% to -$46958.0 in 2024, then jumped by 88.66% to -$5324.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$5324.0 (Q2 2025), -$46958.0 (Q4 2024), and -$38890.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | NutriBand | 41.21 Mn | 36.63 Mn | 88,941.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | -5,324.00 |
| Apr 30, 2025 | -5,324.00 |
| Oct 31, 2024 | -46,958.00 |
| Oct 31, 2024 | -46,958.00 |
| Jul 31, 2024 | -38,890.00 |
| Jul 31, 2024 | -38,890.00 |
| Apr 30, 2024 | -6,195.00 |
| Apr 30, 2024 | -6,195.00 |
| Jan 31, 2024 | -49,137.00 |
| Jan 31, 2024 | -49,137.00 |
| Apr 30, 2023 | -2,624.00 |
| Apr 30, 2023 | -2,624.00 |
| Jan 31, 2023 | -10,023.00 |
| Jan 31, 2023 | -10,023.00 |
| Oct 31, 2022 | -1,272.00 |
| Oct 31, 2022 | -1,272.00 |
| Jul 31, 2022 | -24,206.00 |
| Jul 31, 2022 | -24,206.00 |
| Apr 30, 2022 | -43,803.00 |
| Apr 30, 2022 | -43,803.00 |